JW Lifescience Corporation (234080.KS)
KRW 11220.0
(0.9%)
KRW 11220.0
(0.9%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 20.26 Billion KRW | -2.7% |
| 2022 | 21.03 Billion KRW | 1.4% |
| 2021 | 20.74 Billion KRW | 3.46% |
| 2020 | 20.04 Billion KRW | 6.31% |
| 2019 | 18.85 Billion KRW | 18.05% |
| 2018 | 15.97 Billion KRW | 19.17% |
| 2017 | 13.4 Billion KRW | 5.97% |
| 2016 | 12.64 Billion KRW | 9.53% |
| 2015 | 11.54 Billion KRW | 14.9% |
| 2014 | 10.05 Billion KRW | 14.09% |
| 2013 | 8.8 Billion KRW | 15.48% |
| 2012 | 7.62 Billion KRW | 8.94% |
| 2011 | 7 Billion KRW | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 5.5 Billion KRW | 0.27% |
| 2024 Q1 | 5.49 Billion KRW | -2.51% |
| 2023 Q2 | -5.33 Billion KRW | -214.01% |
| 2023 Q3 | 5.65 Billion KRW | 206.08% |
| 2023 Q4 | 5.63 Billion KRW | -0.42% |
| 2023 FY | 20.46 Billion KRW | -2.7% |
| 2023 Q1 | 4.67 Billion KRW | -8.65% |
| 2022 Q4 | 5.12 Billion KRW | -3.92% |
| 2022 Q1 | 5.04 Billion KRW | -10.78% |
| 2022 Q2 | 5.52 Billion KRW | 9.47% |
| 2022 Q3 | 5.33 Billion KRW | -3.55% |
| 2022 FY | 21.03 Billion KRW | 1.4% |
| 2021 Q2 | 5.52 Billion KRW | 20.38% |
| 2021 FY | 20.74 Billion KRW | 3.46% |
| 2021 Q4 | 5.65 Billion KRW | 13.89% |
| 2021 Q1 | 4.58 Billion KRW | -7.32% |
| 2021 Q3 | 4.96 Billion KRW | -10.02% |
| 2020 Q3 | 4.93 Billion KRW | -2.49% |
| 2020 FY | 20.04 Billion KRW | 6.31% |
| 2020 Q4 | 4.95 Billion KRW | 0.38% |
| 2020 Q1 | 5.1 Billion KRW | 0.56% |
| 2020 Q2 | 5.05 Billion KRW | -0.97% |
| 2019 Q3 | 5.01 Billion KRW | 1.6% |
| 2019 FY | 18.85 Billion KRW | 18.05% |
| 2019 Q4 | 5.07 Billion KRW | 1.27% |
| 2019 Q2 | 4.93 Billion KRW | 25.7% |
| 2019 Q1 | 3.92 Billion KRW | -6.51% |
| 2018 Q4 | 4.2 Billion KRW | 31.69% |
| 2018 Q3 | 3.18 Billion KRW | -30.84% |
| 2018 Q1 | 3.97 Billion KRW | -4.14% |
| 2018 FY | 15.97 Billion KRW | 19.17% |
| 2018 Q2 | 4.61 Billion KRW | 16.16% |
| 2017 Q4 | 4.14 Billion KRW | 43.88% |
| 2017 Q3 | 2.87 Billion KRW | -9.67% |
| 2017 FY | 13.4 Billion KRW | 5.97% |
| 2017 Q2 | 3.18 Billion KRW | -0.28% |
| 2017 Q1 | 3.19 Billion KRW | -6.09% |
| 2016 Q2 | 3.22 Billion KRW | 8.04% |
| 2016 Q4 | 3.4 Billion KRW | 12.35% |
| 2016 Q3 | 3.02 Billion KRW | -6.16% |
| 2016 FY | 12.64 Billion KRW | 9.53% |
| 2016 Q1 | 2.98 Billion KRW | -20.8% |
| 2015 Q4 | 3.77 Billion KRW | 56.72% |
| 2015 Q3 | 2.4 Billion KRW | -11.43% |
| 2015 FY | 11.54 Billion KRW | 14.9% |
| 2015 Q2 | 2.71 Billion KRW | 0.0% |
| 2014 FY | 10.05 Billion KRW | 14.09% |
| 2013 FY | 8.8 Billion KRW | 15.48% |
| 2012 FY | 7.62 Billion KRW | 8.94% |
| 2011 FY | 7 Billion KRW | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Dongwha Pharm.Co.,Ltd | 165.11 Billion KRW | 87.729% |
| Yuhan Corporation | 489.94 Billion KRW | 95.865% |
| Yuhan Corporation | 489.94 Billion KRW | 95.865% |
| Yuyu Pharma, Inc. | 47.25 Billion KRW | 57.122% |
| Yuyu Pharma, Inc. | 47.25 Billion KRW | 57.122% |
| Yuyu Pharma, Inc. | 47.25 Billion KRW | 57.122% |
| Ildong Holdings Co., Ltd. | 278.43 Billion KRW | 92.723% |
| Samil Pharmaceutical Co.,Ltd | 65.75 Billion KRW | 69.185% |
| Dong-A Socio Holdings Co., Ltd. | 297.99 Billion KRW | 93.201% |
| JW Pharmaceutical Corporation | 238.91 Billion KRW | 91.519% |
| JW Pharmaceutical Corporation | 238.91 Billion KRW | 91.519% |
| JW Pharmaceutical Corporation | 238.91 Billion KRW | 91.519% |
| SAMSUNG PHARM. Co., LTD. | 41.78 Billion KRW | 51.515% |
| Chong Kun Dang Holdings Corp. | 350.71 Billion KRW | 94.223% |
| Dong Sung Bio Pharm.Co.,Ltd. | 40.05 Billion KRW | 49.413% |
| HANDOK Inc. | 153.76 Billion KRW | 86.823% |
| Jeil Pharma Holdings Inc | 193.66 Billion KRW | 89.538% |
| Kukje Pharma Co., Ltd. | 69.21 Billion KRW | 70.726% |
| Bukwang Pharmaceutical Co., Ltd. | 87.54 Billion KRW | 76.855% |
| Aprogen pharmaceuticals,Inc. | 58.64 Billion KRW | 65.45% |
| Ilsung Pharmaceuticals Co., Ltd. | 42.47 Billion KRW | 52.294% |
| Daewon Pharmaceutical Co., Ltd. | 221.99 Billion KRW | 90.873% |
| Yungjin Pharm. Co., Ltd. | 69.46 Billion KRW | 70.833% |
| Boryung Corporation | 285.16 Billion KRW | 92.895% |
| Hyundai Pharmaceutical Co., Ltd. | 68.31 Billion KRW | 70.339% |
| Samjin Pharmaceuticals Co., Ltd. | 126.39 Billion KRW | 83.969% |
| Ilyang Pharmaceutical Co.,Ltd | 174.14 Billion KRW | 88.365% |
| Ilyang Pharmaceutical Co.,Ltd | 174.14 Billion KRW | 88.365% |
| Suheung Co., Ltd. | 56.03 Billion KRW | 63.839% |
| Kwang Dong Pharmaceutical Co., Ltd. | 249.12 Billion KRW | 91.867% |
| Hanall Biopharma Co.,Ltd | 71.98 Billion KRW | 71.852% |
| Whan In Pharm Co.,Ltd. | 66.41 Billion KRW | 69.494% |
| MYUNGMOON Pharm co.,Ltd | 93.55 Billion KRW | 78.342% |
| Shin Poong Pharm.Co.,Ltd. | 127.66 Billion KRW | 84.13% |
| Shin Poong Pharm.Co.,Ltd. | 127.66 Billion KRW | 84.13% |
| Korea United Pharm Inc. | 118.21 Billion KRW | 82.86% |
| CKD Bio Corp. | 25.19 Billion KRW | 19.583% |
| Daewoong pharmaceutical Co.,Ltd | 560.43 Billion KRW | 96.385% |
| JW Holdings Corporation | 301.25 Billion KRW | 93.274% |
| REYON Pharmaceutical Co., Ltd. | 75.04 Billion KRW | 73.002% |
| Hanmi Pharm. Co., Ltd. | 610.97 Billion KRW | 96.684% |
| Dong-A ST Co., Ltd. | 306.95 Billion KRW | 93.399% |
| Chong Kun Dang Pharmaceutical Corp. | 408.65 Billion KRW | 95.042% |
| Ildong Pharmaceutical Co., Ltd. | 260.95 Billion KRW | 92.236% |
| Jeil Pharmaceutical Co.,Ltd | 174.92 Billion KRW | 88.417% |
| Hana Pharm Co., Ltd. | 114.72 Billion KRW | 82.339% |